Abstract: The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agents and medicaments comprising such compounds. The compounds are based on a general structure A-L-B, wherein A is a group of formula (II) or of formula (III): or of formula (IV) or of formula (V) B is a group of formula (III), (IV), or (V), or a group of formula (VI) or a group of formula —R10Z, wherein: Z is selected from —CO2R?, —CONR?R?, —SO2R? wherein R? and R? are independently H or C1-C4 alkyl; and R10 is a C1-C4 alkylene or alkenylene group; and L represents a linker group which is a saturated or unsaturated chain of 5 to 13 carbon atoms.

Abstract: The invention comprises an agent for use in medicine, wherein the agent comprises a compound of Formula (I): B-L-B? wherein: B and B? are independently selected from groups of formula (B-I) wherein: Z is selected from —COOH, —CH2COOH, —PO(OH)(OR1), or —CH2PO(OH) (OR1), wherein R1 is H or a phosphate protecting group; W is an alicyclic amine group having from 5 to 12 carbon atoms and at least one amine nitrogen atom; W? is H, or W? is linked to W to form said alicyclic amine group; and Y is selected from —NH—, —N(CH3)—, —CH2—, —NHCO—, —CH2CONH—, —CONH—, CH2NHCO—, or —NHCH2—; and L is a linker group.

Abstract: An agent for use in medicine, wherein the agent comprises a compound of Formula (I): wherein Ar is an aryl linker group, for example a 1,4-phenyl group, including individual pharmaceutically acceptable salts, solvates, prodrugs or derivatives thereof. The compounds of Formula (I) are inhibitors of human C-reactive protein (CRP) and may be used for the treatment of medical conditions mediated by CRP. Also provided are methods of making the compounds of Formula (I) and chemical intermediates thereof.